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Preamble
A primary challenge in the development of clinical practice
guidelines is keeping pace with the stream of new data upon
which recommendations are based. In an effort to respond
more quickly to new evidence, the American College of
Cardiology/American Heart Association (ACC/AHA) Task
Force on Practice Guidelines has created a new “focused
update” process to revise the existing guideline recommen-
dations that are affected by evolving data or opinion. Before
the initiation of this focused approach, periodic updates and
revisions of existing guidelines required up to 3 years tocomplete. Now, however, new evidence will be reviewed in
an ongoing fashion to more efficiently respond to important
science and treatment trends that could have a major impact
on patient outcomes and quality of care. Evidence will be
reviewed at least twice a year, and updates will be initiated on
an as needed basis as quickly as possible, while maintaining
the rigorous methodology that the ACC and AHA have
developed during their more than 20 years of partnership.
These updated guideline recommendations reflect a consensus
of expert opinion following a thorough review that consisted
primarily of late-breaking clinical trials identified through a
broad-based vetting process as important to the relevant patient
population and of other new data deemed to have an impact on
patient care (see Section 1.1 for details on this focused update).
It is important to note that this focused update is not intended to
represent an update based on a full literature review from the
date of the previous guideline publication. Specific criteria/
considerations for inclusion of new data include:
• Publication in a peer-reviewed journal
• Large, randomized, placebo-controlled trial(s)
• Nonrandomized data deemed important on the basis of results
that impact current safety and efficacy assumptions
• Strengths/weakness of research methodology and findings
• Likelihood of additional studies influencing current findings
• Impact on current performance measure(s) and/or likelihood
of the need to develop new performance measure(s)
• Requests and requirements for review and update from the
practice community, key stakeholders, and other sources
free of relationships with industry or other potential bias
• Number of previous trials showing consistent results
• Need for consistency with other guidelines or guideline
revisions
In analyzing the data and developing updated recommen-
dations and supporting text, the focused update writing group
used evidence-based methodologies developed by the ACC/
AHA Task Force on Practice Guidelines, which are described
elsewhere.1,2
The schema for class of recommendation and level of evi-
dence is summarized in Table 1, which also illustrates how the
grading system provides estimates of the size of the treatment
effect and the certainty of the treatment effect. Note that a
recommendation with Level of Evidence B or C does not imply
that the recommendation is weak. Many important clinical
questions addressed in guidelines do not lend themselves to
clinical trials. Although randomized trials may not be available,
there may be a very clear clinical consensus that a particular test
or therapy is useful and effective. Both the class of recommen-
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 dation and level of evidence listed in the focused updates are
based on consideration of the evidence reviewed in previous
iterations of the guidelines as well as the focused update. Of
note, the implications of older studies that have informed
recommendations but have not been repeated in contemporary
settings are carefully considered.
The ACC/AHA practice guidelines address patient popula-
tions (and health care providers) residing in North America. As
such, drugs that are not currently available in North America are
discussed in the text without a specific class of recommendation.
For studies performed in large numbers of subjects outside of
North America, each writing committee reviews the potential
impact of different practice patterns and patient populations on the
Table 1. Applying Classification of Recommendations and Level
Data available from clinical trials or registries about the usefulness/efficac
myocardial infarction, history of heart failure, and prior aspirin use. A recommen
Many important clinical questions addressed in the guidelines do not lend the
be a very clear clinical consensus that a particular test or therapy is useful o
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed
recommendations have been written in full sentences that express a complet
the rest of the document (including headings above sets of recommendations
increase readers’ comprehension of the guidelines and will allow queries at ttreatment effect and on the relevance to the ACC/AHA targetpopulation to determine whether the findings should inform a
specific recommendation.
The ACC/AHA practice guidelines are intended to assist
health care providers in clinical decision making by
describing a range of generally acceptable approaches for
the diagnosis, management, and prevention of specific
diseases or conditions. The guidelines attempt to define
practices that meet the needs of most patients in most
circumstances. The ultimate judgment regarding care of a
particular patient must be made by the health care provider
and patient in light of all the circumstances presented by
that patient. Thus, there are circumstances in which devi-
ations from these guidelines may be appropriate. Clinical
ence†
rent subpopulations, such as gender, age, history of diabetes, history of prior
ith Level of Evidence B or C does not imply that the recommendation is weak.
to clinical trials. Even though randomized trials are not available, there may
ve.
suggested phrases to use when writing recommendations. All guideline
ht, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
idual recommendation level.of Evid
y in diffe
dation w
mselves
r effecti
a list of
e thoug
), would
he indivdecision making should consider the quality and availabil-
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 ity of expertise in the area where care is provided. These
guidelines may be used as the basis for regulatory or payer
decisions, but the ultimate goal is quality of care and
serving the patient’s best interests.
Prescribed courses of treatment in accordance with these
recommendations are only effective if they are followed by
the patient. Because lack of patient adherence may adversely
affect treatment outcomes, health care providers should make
every effort to engage the patient in active participation with
prescribed treatment.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived
conflict of interest arising from industry relationships or
personal interests of a writing committee member. All writing
committee members and peer reviewers were required to
provide disclosure statements of all such relationships per-
taining to the trials and other evidence under consideration
(see Appendixes 1 and 2). Final recommendations were
balloted to all writing committee members. Writing commit-
tee members with significant (greater than $10 000) relevant
relationships with industry (RWI) were required to recuse
themselves from voting on that recommendation. Writing
committee members who did not participate are not listed as
authors of this focused update.
With the exception of the recommendations presented here,
the full guidelines remain current. Only the recommendations
from the affected section(s) of the full guidelines are included
in this focused update. For easy reference, all recommenda-
tions from any section of guidelines impacted by a change are
presented with a notation as to whether they remain current,
are new, or have been modified. When evidence impacts
recommendations in more than 1 set of guidelines, those
guidelines are updated concurrently.
The recommendations in this focused update will be
considered current until they are superseded by another
focused update or the full-text guidelines are revised. This
focused update is published in the January 15, 2008, issue of
the Journal of the American College of Cardiology and the
January 15, 2008, issue of Circulation as an update to the
full-text guidelines and is also posted on the ACC (www.
acc.org) and AHA (www.americanheart.org) Web sites. Cop-
ies of the focused update are available from both organiza-
tions.
Sidney C. Smith, Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACC/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Evidence Review
Late-breaking clinical trials presented at the 2005 and
2006 annual scientific meetings of the ACC, AHA, and
European Society of Cardiology, as well as selected other
data, were reviewed by the standing guideline writing
committee along with the parent Task Force and other
experts to identify those trials and other key data that
might impact guidelines recommendations. On the basis ofthe criteria/considerations noted above, recent trial data
and other clinical information were considered important
enough to prompt a focused update of the 2004 ACC/AHA
Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction [see Chen ZM et al.3;
Chen ZM et al.4; ASSENT-4 PCI5; Antman EM et al.6;
Yusuf S et al.7; Bhatt DL et al.8; Sabatine MS et al.9;
Bennett JS et al.10; Smith SC Jr et al.11; OAT12,13 and
TOSCA14].
When considering the new data for this focused update,
the writing group faced the task of weighing evidence from
studies enrolling large numbers of subjects outside North
America. Although noting that practice patterns and the
rigor applied to data collection, as well as the genetic
makeup of subjects, might influence the observed magni-
tude of a treatment effect, the writing group believed the
data were relevant to formulation of recommendations
for management of ST-elevation myocardial infarction
(STEMI) in North America. The reasons for this decision
include that 1) a broad array of management strategies
was represented, including substantial proportions of sub-
jects who received some form of reperfusion therapy, 2)
concomitant treatments with proven efficacy (e.g., aspirin,
beta blockers, inhibitors of the renin-angiotensin-
aldosterone system, and statins) were used in the majority
of patients, and 3) it was considered an impractical
expectation that the tens of thousands of patients with
STEMI needed to meet the estimated sample size for
contemporary clinical trials be enrolled exclusively at
North American sites.
To provide clinicians with a comprehensive set of data,
whenever possible the exact event rates in various treat-
ment arms of clinical trials are presented to permit calcu-
lation of the absolute risk difference (ARD) and number
needed to treat (NNT) or harm (NNH); the relative
treatment effects are described either as odds ratio (OR),
relative risk (RR), or hazard ratio (HR), depending on the
format in the original publication.
Consult the full-text version or executive summary of
the 2004 ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction15 for
policy on clinical areas not covered by the focused update.
Individual recommendations updated in this focused up-
date will be incorporated into future revisions and/or
updates of the full-text guidelines.
1.2. Organization of Committee and
Relationships With Industry
For this focused update, all members of the 2004 STEMI
writing committee were invited to participate; those who
agreed (referred to as the 2007 focused update writing
group) were required to disclose all RWI relevant to the
data under consideration.2 Focused update writing group
members who had no significant relevant RWI wrote the
first draft of the focused update; the draft was then
reviewed and revised by the full writing group. Each
recommendation required a confidential vote by the writ-
ing group members before external review of the docu-
ment. Any writing committee member with a significant
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 (greater than $10 000) relationship with industry relevant
to the recommendation was recused from voting on that
recommendation.
1.3. Review and Approval
This document was reviewed by 3 outside reviewers
nominated by the ACC and 3 outside reviewers nominated
by the AHA, as well as 1 reviewer each from the American
Academy of Family Physicians and the Canadian Cardio-
vascular Society (CCS) and 58 individual content review-
ers. All reviewer RWI information was collected and
distributed to the writing committee and is published in
this document (see Appendix 2 for details).
This document was approved for publication by the gov-
erning bodies of the American College of Cardiology Foun-
dation and the American Heart Association and endorsed by
the American Academy of Family Physicians and the
Canadian Cardiovascular Society.
2. Analgesia
Analysis of retrospective data16 has raised a question about
the potentially adverse effects of morphine in patients with
unstable angina (UA)/non–ST-elevation myocardial infarc-
tion (NSTEMI). As a result, the recommendation for mor-
phine pain relief has been reduced to a Class IIa recommen-
dation for that patient population. Use of morphine remains a
Class I recommendation for patients with STEMI, however,
because STEMI patients should either have received reperfu-
sion or are not candidates for reperfusion, and continuing pain
requires relief in either case (Table 2).
Because of the known increased risk of cardiovascular
events among patients taking cyclooxygenase-2 (COX-2)
inhibitors and other nonsteroidal anti-inflammatory drugs
(NSAIDs),17–19 these drugs should be discontinued immedi-
ately at the time of STEMI (see 2004 STEMI Guidelines,
Section 7.12.5, for additional discussion).3,15,20,21 A substudy
analysis from the ExTRACT TIMI-25 (Enoxaparin and
Thrombolysis Reperfusion for Acute Myocardial Infarction
Table 2. Updates to Section 6.3.1.3: Analgesia
2004 STEMI Guideline Recommendation 2
Morphine sulfate (2 to 4 mg IV with increments of 2 to 8 mg
IV repeated at 5- to 15-minute intervals) is the analgesic of
choice for management of pain associated with STEMI. (Level
of Evidence: C)
1. Morphine su
repeated at
managemen
2. Patients rou
nonselective
should have
presentation
reinfarction,
associated w
1. NSAIDs (exc
selective ag
for STEMI b
hypertension
their use. (LCOX-2 indicates cyclooxygenase-2; IV, intravenous/intravenously; NSAIDs, nonsteroTreatment–Thrombolysis in Myocardial Infarction) trial22
demonstrated an increased risk of death, reinfarction, heart
failure, or shock among patients who were taking NSAIDs
within 7 days of enrollment. Longer-term management con-
siderations and a discussion of the gradient of risk with the
various NSAIDS are found in Section 7.12.5 of the 2004
STEMI Guidelines.15
3. Beta Blockers
The 2004 STEMI Guidelines recommendations (Table 3)
were based on studies that showed a reduced incidence of
subsequent reinfarction and recurrent ischemia in patients
receiving both fibrinolytic therapy and intravenous (IV) beta
blockers. However, uncertainty about the use of IV beta
blockers in the setting of fibrinolytic therapy has increased
following 2 later randomized trials of IV beta blockade,23,24 a
post-hoc analysis of the use of atenolol in the GUSTO-I
(Global Utilization of Streptokinase and TPA for Occluded
Coronary Arteries) trial,25 and a review of early beta-blocker
therapy in myocardial infarction (MI)26 that did not find
significant reductions in mortality.15
3.1. COMMIT/CCS-2 (Metoprolol)
The COMMIT/CCS-2 (Clopidogrel and Metoprolol in Myo-
cardial Infarction Trial/Second Chinese Cardiac Study) (4)
randomized 45 852 patients within 24 hours of onset of
suspected MI to receive metoprolol (up to 3 doses of 5 mg IV
each in the first 15 minutes, followed by 200 mg orally daily)
or matching placebo. Fifteen minutes after the IV doses, a
50-mg tablet of metoprolol or placebo was administered
orally and repeated every 6 hours during Days 0 to 1 of
hospitalization. From Day 2 onward, 200 mg of controlled-
release metoprolol or placebo was administered orally daily
(this is the Food and Drug Administration [FDA]-approved
regimen for metoprolol in MI) until discharge from the
hospital or up to a maximum of 4 weeks in hospital (in
survivors, the mean was 15 days). The 2 prespecified co-
primary outcomes were the composite of death, reinfarction,
I Focused Update Recommendation Comments
4 mg IV with increments of 2 to 8 mg IV
minute intervals) is the analgesic of choice for
associated with STEMI. (Level of Evidence: C)
2004 recommendation
remains current in 2007
Update
ing NSAIDs (except for aspirin), both
as COX-2 selective agents, before STEMI
gents discontinued at the time of
EMI because of the increased risk of mortality,
sion, heart failure, and myocardial rupture
use. (Level of Evidence: C)
New recommendation
spirin), both nonselective as well as COX-2
uld not be administered during hospitalization
f the increased risk of mortality, reinfarction,
ailure, and myocardial rupture associated with
vidence: C)
New recommendation007 STEM
Class I
lfate (2 to
5- to 15-
t of pain
tinely tak
as well
those a
with ST
hyperten
ith their
Class III
ept for a
ents, sho
ecause o
, heart f
evel of Eidal anti-inflammatory drugs; and STEMI, ST-elevation myocardial infarction.
rcutane
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 or cardiac arrest and death from any cause during the
scheduled treatment period.
Neither of the co-primary study end points was signifi-
cantly reduced by allocation to metoprolol. For every 1000
patients treated, allocation to metoprolol was associated with
5 fewer episodes of reinfarction, 5 fewer episodes of ventric-
ular defibrillation, but 11 more episodes of cardiogenic shock.
The excess of cardiogenic shock was seen chiefly from Days
0 to 1 after hospitalization, whereas the reductions in rein-
farction and ventricular fibrillation appeared from Day 2
onward.
Allocation to metoprolol produced an average relative in-
crease in cardiogenic shock of 30%, with higher rates for those
greater than 70 years of age, or with systolic blood pressure less
than 120 mm Hg, or with presenting heart rate greater than 110
bpm, or with Killip class greater than 1. On average across the
whole study population, the absolute reduction in arrhythmia-
related deaths and the absolute increase in cardiogenic shock–
related deaths were of similar magnitude. No apparent difference
was noted between the 2 treatment groups in the other attributed
causes of death, either individually or in aggregate. Metoprolol
allocation was associated with significantly more persistent
hypotension and more cases of bradycardia.
Though patients at high or low risk could be identified, the
authors noted that they were not able to identify any sub-
Table 3. Updates to Section 6.3.1.5: Beta Blockers
2004 STEMI Guideline Recommendation 2007
Oral beta-blocker therapy should be administered
promptly to those patients without a contraindication,
irrespective of concomitant fibrinolytic therapy or
performance of primary PCI. (Level of Evidence: A)
1. Oral beta-blocker therap
not have any of the follo
state, 3) increased risk*
beta blockade (PR interv
block, active asthma, or
Patients with early contraindications within the first 24
hours of STEMI should be reevaluated for candidacy for
beta-blocker therapy as secondary prevention. (Level of
Evidence: C)
2. Patients with early contr
reevaluated for candidac
Evidence: C)
Patients with moderate or severe LV failure should
receive beta-blocker therapy as secondary prevention
with a gradual titration scheme. (Level of Evidence: B)
3. Patients with moderate o
secondary prevention wi
It is reasonable to administer IV beta blockers promptly
to STEMI patients without contraindications, especially if
a tachyarrhythmia or hypertension is present. (Level of
Evidence: B)
1. It is reasonable to admin
patients who are hyperte
heart failure, 2) evidence
shock, or 4) other relativ
0.24 seconds, second- o
disease). (Level of Evide
1. IV beta blockers should
following: 1) signs of he
for cardiogenic shock, o
interval greater than 0.2
or reactive airway disea
*Risk factors for cardiogenic shock (the greater the number of risk factors
years, systolic blood pressure less than 120 mm Hg, sinus tachycardia great
symptoms of STEMI.
IV indicates intravenous; LOE, level of evidence; LV, left ventricular; PCI, pegroups in which the benefits clearly outweighed the risks.3.2. Conclusion
This focused update expands on the concepts introduced in
the 2004 STEMI Guidelines, underscoring the potential
risk of administering IV beta blockers to patients with
severe heart failure or cardiogenic shock. There are several
circumstances in which it can be useful (Class IIa) to
administer an IV beta blocker acutely to a STEMI patient
(Table 3), and these situations are discussed below. It is
reasonable to administer IV beta-blocker therapy on Days
0 to 1 of hospitalization for STEMI when hypertension is
present and the patient is not at an increased risk of
cardiogenic shock on the basis of the risk factors defined
above. Patients with sinus tachycardia or atrial fibrillation
should have left ventricular (LV) function rapidly evalu-
ated before administration of IV beta blockers (or other
negative inotropes, such as non-dihydropyridine calcium
channel blockers). From Day 2 onward, when beneficial
effects on reinfarction and ventricular fibrillation are seen,
administration of 200 mg of controlled-release oral meto-
prolol daily appears to be safe in hemodynamically stable
patients with STEMI who are free of contraindications. It
is prudent to initiate a dose of 50 mg of metoprolol orally
every 6 hours, transitioning to a dose equivalent to 200 mg
per day orally or the maximum tolerated dose. It should be
noted that long-term use of oral beta blockers is strongly
ocused Update Recommendation Comments
be initiated in the first 24 hours for patients who do
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 ary prevention in patients at highest risk, such as those
with low ejection fraction, heart failure, or postshock, once
they have stabilized, with gradual dose titration27 (see the
2004 STEMI Guidelines, Sections 7.4.1 and 7.12.7).15
The results of the COMMIT-CCS 2 trial raise questions
about the safety of early use of IV beta blockers, particularly
in high-risk populations, and led the writing group to reex-
amine the overall evidence base for beta-blocker therapy. The
evidence base for this therapy was developed more than 25
years ago in a treatment environment that differs from
contemporary practice. Moreover, no study included an oral
beta blocker–only arm. The writing group consensus, how-
ever, was not to change the classification of the current early
oral beta-blocker recommendation but to restrict it to patients
who are not at high risk for complications. In addition,
because of the absence of a study that specifically evaluated
oral therapy alone, the Level of Evidence has been changed
from A to B. Nevertheless, early (within 24 hours) oral
beta-blocker therapy remains a Class I recommendation for
those patients who are not at high risk for complications.
Whether this change should affect current performance
measures is beyond the scope of this document. The
findings of potential risk of beta-blocker therapy in
COMMIT emphasize the importance of continually mon-
itoring these patients throughout hospitalization for signs
and symptoms of complications of therapy, as noted in
other sections of the original guidelines (Sections 6.3.1.5,
7.4.1, and 7.12.7). Because of the uncertainty about the
benefit of oral beta blockers early on (e.g., in COMMIT-
CCS 2, Days 0 to 1), the writing group recommends further
research and additional examination at the time of the next
revision to the STEMI Guidelines.
4. Reperfusion
4.1. Logistics of Care
Regardless of the mode of reperfusion, the overarching
concept is to minimize total ischemic time, which is defined
as the time from onset of symptoms of STEMI to initiation of
reperfusion therapy. It is increasingly clear that 2 types of
hospital systems provide reperfusion therapy: those with
percutaneous coronary intervention (PCI) capability and
those without PCI capability. When PCI capability is avail-
able, the best outcomes are achieved by offering this strategy
24 hours per day, 7 days per week.28 The systems goal should
Table 4. Updates to Section 6.3.1.6: Reperfusion
2004 STEMI Guideline Recommendation 20
Primary PCI should be performed as quickly as possible with
the goal of a medical contact–to-balloon or door-to-balloon
interval of within 90 minutes. (Level of Evidence: B)
1. STEMI patients p
with primary PCI
a systems goal.
STEMI patients presenting to a facility without the capability for
expert, prompt intervention with primary PCI within 90 minutes
of first medical contact should undergo fibrinolytic therapy
unless contraindicated. (Level of Evidence: A)
2. STEMI patients p
be transferred to
medical contact
within 30 minute
fibrinolytic therapPCI indicates primary coronary intervention; LOE, level of evidence; and STEMI, STbe a first medical contact–to-balloon time within 90 minutes
(Table 4, Figure 1). There should be an ongoing program of
outcomes analysis and periodic case review to identify
process-of-care strategies that will continually improve time
to treatment and facilitate rapid and appropriate treatment. A
comprehensive effort in this regard is the AHA Mission
Lifeline program, a community-based national initiative to
improve the quality of care and outcomes of patients with
STEMI by improving health care system readiness and
response to STEMI.29 The “Door-to-Balloon (D2B): An
Alliance for Quality” campaign (www.d2balliance.org),
launched by the ACC in collaboration with many organiza-
tions, including the AHA, aims to improve the timeliness of
primary PCI. The goal is to increase the percentage of
patients who receive timely primary PCI, with an emphasis
on having at least 75% of patients treated within 90 minutes
of presentation at the hospital, with a recommendation for the
use of evidence-based strategies to reduce needless delays.30
The 75% goal was set in recognition that some patients have
clinically relevant non–system-based delays that do not rep-
resent quality-of-care issues. In hospitals without PCI capa-
bility, immediate transfer for primary PCI is a treatment
option when the expected door-to-balloon time is within 90
minutes of first medical contact.31,32
It is important to note that the door-to-balloon goal is a
systems goal that may not be possible to achieve for an
individual patient because of patient variables (uncertainty
about diagnosis, evaluation and treatment of other life-
threatening conditions, obtaining informed consent, etc.)
that delay the patient’s arrival in the interventional cardi-
ology laboratory or anatomical challenges (issues of arte-
rial, coronary, or lesion access) that prolong the PCI
procedure. In the absence of such circumstances, however,
reperfusion should be achieved as soon as possible within
this time, and many hospitals with refined systems are
approaching median door-to-balloon times of 60 to 70
minutes. Discussions about measurement, particularly with
respect to inclusion criteria and the appropriate time to end
measurement, are beyond the scope of this document and
are being considered by groups that are focusing on how to
improve the alignment between what is measured and
patient outcomes. The focus on measurement should not
displace the emphasis on improving processes that will
facilitate more rapid treatment that is delivered safely and
appropriately. This committee continues to endorse the
I Focused Update Recommendation Comments
to a hospital with PCI capability should be treated
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Modified recommendation
(changed LOE and text)
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 concept that faster times to reperfusion and better
systems of care are associated with important reduc-
tions in morbidity and mortality rates in patients with
STEMI. An underutilized but effective strategy for
improving systems of care for STEMI patients is to
expand the use of prehospital 12-lead electrocardiogra-
phy programs by emergency medical systems (EMS)
that provide advanced life support.33,34
The emphasis on primary PCI should not obscure the
Figure 1. Options for Transportation of STEMI Patients and Initia
Reperfusion in patients with STEMI can be accomplished by pharmacological (fibrinolysis) or ca
120 minutes (ideally within 60 minutes) from symptom onset to initiation of reperfusion treatm
transportation and the capabilities of the receiving hospital:
Medical System Goals: EMS Transport (Recommended):
• If EMS has fibrinolytic capability and the patient qualifies for therapy, prehospital fibrinolysis
• If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to
fibrinolysis is indicated.
• If EMS is not capable of administering prehospital fibrinolysis and the patient is transported
• If EMS takes the patient to a non–PCI-capable hospital, it is appropriate to consider emergency i
X There is a contraindication to fibrinolysis.
X PCI can be initiated promptly within 90 minutes from EMS arrival-to-balloon time at th
X Fibrinolysis is administered and is unsuccessful (i.e., “rescue PCI”).
Patient Self-Transport (Discouraged):
• If the patient arrives at a non–PCI-capable hospital, the door-to-needle time should be with
• If the patient arrives at a PCI-capable hospital, the door-to-balloon time should be within 9
• If the patient presents to a non–PCI-capable hospital, it is appropriate to consider emergenc
X There is a contraindication to fibrinolysis.
X PCI can be initiated within 90 minutes after the patient presented to the initial receiving ho
at the initial receiving hospital.
X Fibrinolysis is administered and is unsuccessful (i.e., “rescue PCI”).
*The medical system goal is to facilitate rapid recognition and treatment of patients with STEMI
within 30 minutes or door-to-balloon (or medical contact-to-balloon) for PCI can be achieved
that should be considered acceptable for a given system. Systems that are able to achieve even
is defined as “time of EMS arrival on scene” after the patient calls EMS/9-1-1 or “time of arrival
transports himself/herself to the hospital.
†EMS Arrival¡Transport to non–PCI-capable hospital¡Arrival at non–PCI-capable hospital t
EMS indicates emergency medical system; PCI, percutaneous coronary intervention; and STE
Modified with permission.15,90importance of fibrinolytic therapy. Many hospital systems inNorth America do not have the capability of meeting the time
goal for primary PCI.35 Therefore, because of the critical
importance of time to treatment from onset of symptoms of
STEMI in reducing morbidity and mortality, fibrinolytic
therapy is preferred. In these settings, transfer protocols need
to be in place for arranging rescue PCI when clinically
indicated.36
For fibrinolytic therapy, the system goal is to deliver the
drug within 30 minutes of the time that the patient presents to
rfusion Treatment Goals
sed (primary PCI) approaches. The overarching goal is to keep total ischemic time within
in this context, the following are goals for the medical system* based on the mode of patient
e started within 30 minutes of arrival of EMS on the scene.
I-capable hospital, the door-to-needle time should be within 30 minutes for patients for whom
apable hospital, the EMS arrival-to-balloon time should be within 90 minutes.
l transfer of the patient to a PCI-capable hospital for mechanical revascularization if
pable hospital.†
utes of arrival at the emergency department.
.
pital transfer of the patient to a PCI-capable hospital if
ithin 60 minutes compared with when fibrinolysis with a fibrin-specific agent could be initiated
or-to-needle (ormedical contact-to-needle) for initiation of fibrinolytic therapy can be achieved
0 minutes. These goals should not be understood as “ideal” times but rather the longest times
pid times for treatment of patients with STEMI should be encouraged. Note “medical contact”
ergency department door” (whether PCI-capable or non–PCI-capable hospital) when the patient
to PCI-capable hospital¡Arrival at PCI-capable hospital-to-balloon time90 minutes.
evation myocardial infarction.l Repe
theter-ba
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 medical contact because in regionalization strategies, extra
time may be taken to transport patients to a center that
performs the procedure. Consequently, it is important to
consider the time from first medical contact. The writing
group does believe that every effort should be made to reduce
the time from first medical contact to fibrinolytic therapy
when that is considered the appropriate reperfusion strategy.
5. Facilitated PCI
Facilitated PCI refers to a strategy of planned immediate PCI
after administration of an initial pharmacological regimen
intended to improve coronary patency before the procedure.
These regimens have included high-dose heparin, platelet
glycoprotein (GP) IIb/IIIa inhibitors, full-dose or reduced-
dose fibrinolytic therapy, and the combination of a GP IIb/IIIa
inhibitor with a reduced-dose fibrinolytic agent (e.g., fibrino-
lytic dose typically reduced 50%). Facilitated PCI should be
differentiated from primary PCI without fibrinolytic therapy,
from primary PCI with a GP IIb/IIIa inhibitor started at the
time of PCI, from early or delayed PCI after successful
fibrinolytic therapy, and from rescue PCI after unsuccessful
fibrinolytic therapy. Potential advantages of facilitated PCI
include earlier time to reperfusion, smaller infarct size,
improved patient stability, lower infarct artery thrombus
burden, greater procedural success rates, higher TIMI
(Thrombolysis in Myocardial Infarction trial) flow rates, and
improved survival rates. Potential risks include increased
bleeding complications, especially in older patients. Potential
limitations include additional cost.37
Despite the potential advantages, clinical trials of facili-
tated PCI have not demonstrated any benefit in reducing
infarct size or improving outcomes. The largest of these was
the ASSENT-4 PCI (Assessment of the Safety and Efficacy of
a New Treatment Strategy with Percutaneous Coronary In-
tervention) trial,5 in which 1667 patients were randomized to
receive full-dose tenecteplase and PCI versus primary PCI.
The trial was terminated prematurely because of a higher
in-hospital mortality rate in the facilitated PCI group (6% vs.
3%; p0.01). The primary end point, a composite of death,
shock, and congestive heart failure within 90 days, was
significantly higher with facilitated PCI than with primary
PCI (18.6% vs. 13.4%; p0.0045), and there was a trend
toward a higher 90-day mortality rate (6.7% vs. 4.9%;
Table 5. Updates to Section 6.3.1.6.4.4: Facilitated PCI
2004 STEMI Guideline Recommendation 2007 STEM
Facilitated PCI might be performed as a
reperfusion strategy in higher-risk patients
when PCI is not immediately available and
bleeding risk is low. (Level of Evidence: B)
1. Facilitated PCI using regimens o
considered as a reperfusion stra
a. Patients are at high risk, b. P
Bleeding risk is low (younger ag
weight). (Level of Evidence: C)
1. A planned reperfusion strategy u
PCI may be harmful. (Level of ELOE indicates level of evidence; PCI, percutaneous coronary intervention, and STEMp0.14). Defenders of the facilitated PCI strategy point out
that the absence of an infusion of heparin after bolus
administration and the absence of a loading dose of clopi-
dogrel, plus prohibition of GP IIb/IIIa inhibitors except in
bail-out situations, made adjunctive antithrombotic therapy
suboptimal for the facilitated PCI group. Moreover, the
median treatment delay between administration of tenect-
eplase and PCI was only 104 minutes, and mortality rates
were higher in PCI centers. The evidence on whether earlier
(prehospital) administration of fibrinolytic therapy, better
antithrombotic therapy, longer delays to PCI, or selective use
of PCI as a rescue strategy would make the facilitated PCI
strategy beneficial is unclear. These issues require further
study. On the basis of these data, however, facilitated PCI
offered no clinical benefit.
Keeley and coworkers performed a quantitative review of
17 trials that compared facilitated PCI with primary PCI38
(Figure 2). Nine trials involved GP IIb/IIIa inhibitors alone
(n1148), 6 trials with fibrinolytic therapy (including
ASSENT-4 PCI) (n2953), and 2 trials with a fibrinolytic
agent plus a GP IIb/IIIa inhibitor (n399). Facilitated PCI
with fibrinolytic therapy had significantly higher rates of
mortality, nonfatal reinfarction, urgent target-vessel revascu-
larization, total and hemorrhagic stroke, and major bleeding
compared with primary PCI. There were no differences in
efficacy or safety when facilitated PCI with a GP IIb/IIIa
inhibitor was compared with primary PCI.
A planned reperfusion strategy using full-dose fibrino-
lytic therapy followed by immediate PCI may be harmful
(Table 5). Nevertheless, selective use of the facilitated
strategy with regimens other than full-dose fibrinolytic
therapy in subgroups of patients at high risk (large MI or
hemodynamic or electrical instability) with low risk of
bleeding who present to hospitals without PCI capability
might be performed when transfer delays for primary PCI
are anticipated. Although quantitative analysis showed no
advantage for pretreatment with a GP IIb/IIIa inhibitor, it
did not document any major disadvantage either. The use
of GP IIb/IIIa inhibitors, particularly abciximab, during
primary PCI is well established.55 Further trials of
reduced-dose fibrinolytic therapy, with or without GP
IIb/IIIa inhibitors, are in progress and may yield different
efficacy and/or safety results.
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 6. Immediate or Emergency Invasive Strategy
and Rescue PCI
Pharmacological reperfusion with full-dose fibrinolysis is
not uniformly successful in restoring antegrade flow in the
infarct artery. In such situations, a strategy of prompt
coronary angiography with intent to perform PCI is fre-
quently contemplated. In certain patients, such as those
with cardiogenic shock (especially those less than 75 years
of age), severe congestive heart failure/pulmonary edema,
or hemodynamically compromising ventricular arrhyth-
mias (regardless of age), a strategy of coronary angiogra-
phy with intent to perform PCI is a useful approach
regardless of the time since initiation of fibrinolytic
therapy, provided further invasive management is not
considered futile or unsuitable given the clinical circum-
stances (Table 6). Further discussion of the management of
such patients may be found in the 2004 STEMI Guidelines
(see Section 6.3.1.6.4.6, as well as Sections 7.6.3 through
7.6.6).15 These sections have not been updated in this
document.
In other patients who do not exhibit the clinical instability
noted above, PCI may also be reasonable if there is clinical
suspicion of failure of fibrinolysis. This is referred to as
rescue PCI. Critical to the success of rescue PCI is the initial
clinical identification of patients who are suspected of having
failed reperfusion with full-dose fibrinolysis. Because the
presence or absence of ischemic discomfort may be unreli-
able for identifying failed reperfusion, clinicians should
search for evidence of inadequate ST-segment resolution on
Figure 2. Short-Term Death in Patients Treated With Facilitated
and squares indicate odds ratios. Lines indicate 95% confidencethe 12-lead electrocardiogram (ECG). Operationally, the12-lead ECG should be scrutinized after adequate time has
elapsed before it is decided that fibrinolytic therapy has not
been effective. Although earlier times have been used in some
studies, the writing committee believed that 90 minutes after
initiation of fibrinolysis was the best time point for evaluating
the need for rescue PCI; hence, if there is less than 50% ST
resolution in the lead showing the greatest degree of ST-segment
elevation at presentation, fibrinolytic therapy has likely failed to
produce reperfusion.
The 2004 STEMI Guidelines recommendations for rescue
PCI were based on observational data and the results of 2 small
randomized clinical trials (n179) from the early 1990s.56,57
More recently, MERLIN (Middlesbrough Early Revasculariza-
tion to Limit INfarction) (n307), REACT (Rescue Angioplasty
versus Conservative Treatment or Repeat Thrombolysis)
(n427), and 3 meta-analyses have refocused attention on
rescue PCI.58–62 This subject has been studied with fewer than
1000 patients enrolled in randomized trials.
In the period between trials studying rescue PCI, there was
a transition between angiographic and electrocardiographic
diagnosis to detect failed reperfusion. Importantly, in the
earlier studies, rescue PCI was performed in infarct arteries
with TIMI 0/1 flow, often after a protocol-mandated 90-
minute angiogram. In MERLIN and REACT, however, pa-
tients were randomized if they had less than 50% ST-segment
elevation resolution at 60 or 90 minutes, respectively. Many
patients had patent infarct arteries on angiography; only 54%
of patients in MERLIN and 74% of patients in REACT
(which required less than TIMI grade 3 flow for PCI) actually
ary PCI. Trials were classified by facilitated regimen. Diamonds
ls. Reprinted with permission.38underwent PCI. From a procedural standpoint, stents have
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replaced balloon angioplasty, antiplatelet therapy has im-
proved with the addition of a thienopyridine agent and often
a GP IIb/IIIa receptor antagonist, and procedural success rates
are higher.
Despite these historical differences, recent data support the
initial observation that rescue PCI decreases adverse clinical
events compared with medical therapy. In the Wijeysundera
meta-analysis62 (Figure 3), there was a trend toward reduced
mortality rates with rescue PCI from 10.4% to 7.3% (RR 0.69
[95% confidence interval (CI) 0.46 to 1.05]; p0.09), re-
duced reinfarction rates from 10.7% to 6.1% (RR 0.58 [95%
CI 0.35 to 0.97]; p0.04), and reduced heart failure rates
from 17.8% to 12.7% (RR 0.73 [95% CI 0.54 to 1.00];
p0.05). These event rates suggest that high-risk patients
Table 6. Updates to Section 6.3.1.6.4.5: Immediate (or Emergenc
2004 STEMI Guideline Recommendation 2
Rescue PCI should be performed in patients less than 75 years
old with ST elevation or left bundle-branch block who develop
shock within 36 hours of MI and are suitable for revascularization
that can be performed within 18 hours of shock unless further
support is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive care. (Level of
Evidence: B)
1. A strategy of
emergency CA
fibrinolytic the
a. Cardiogenic
candidates
b. Severe con
III) (Level o
c. Hemodynam
Evidence: C
Rescue PCI is reasonable for selected patients 75 years or older
with ST elevation or left bundle-branch block or who develop
shock within 36 hours of MI and who are suitable for
revascularization that can be performed within 18 hours of shock.
Patients with good prior functional status who are suitable for
revascularization and who agree to invasive care may be selected
for such an invasive strategy. (Level of Evidence: B)
1. A strategy of
emergency CA
have received
that they are
B)
It is reasonable to perform rescue PCI for patients with 1 or more
of the following:
a. Hemodynamic or electrical instability. (Level of Evidence: C)
b. Persistent ischemic symptoms. (Level of Evidence: C)
2. It is reasonab
following:
a. Hemodynam
b. Persistent
3. A strategy of
reasonable fo
segment elev
initiation of fib
elevation) and
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segment depr
Rescue PCI in the absence of 1 or more of the above Class I or
IIa indications is not recommended. (Level of Evidence: C)
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earlier it is in
Evidence: C)
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emergency C
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the patient or
Evidence: C)
CABG indicates coronary artery bypass graft; COR, class of recommenda
intervention; and STEMI, ST-elevation myocardial infarction.were selected for enrollment, so these data do not inform theclinical community about the role of rescue PCI in lower-risk
patients. Also, the benefits of rescue PCI need to be balanced
against the risk. There was an excess occurrence of stroke in
2 trials (10 events vs. 2 events), but the majority of the strokes
were thromboembolic rather than hemorrhagic, and the sam-
ple size was small, so more data are needed to define this risk.
There also was an increase in absolute risk of bleeding of
13%, suggesting that adjustments in antithrombotic medica-
tion dosing are needed to improve safety. It should be noted
that the majority of patients who underwent rescue PCI
received fibrinolytic therapy with streptokinase.
Given the association between bleeding events and subse-
quent ischemic events,63 it might be reasonable to select
moderate- and high-risk patients for PCI after fibrinolysis and to
sive Strategy and Rescue PCI
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 patients with cardiogenic shock, severe heart failure, or hemo-
dynamically compromising ventricular arrhythmias are excellent
candidates. An ECG estimate of potential infarct size in patients
with persistent ST-segment elevation (less than 50% resolution
at 90 minutes following initiation of fibrinolytic therapy in the
lead showing the worst initial evaluation) and ongoing ischemic
pain is useful for selecting other patients for rescue PCI. Anterior
MI or inferior MI with right ventricular involvement or precor-
dial ST-segment depression usually predicts increased risk.64
Conversely, patients with symptom resolution, improving ST-
segment elevation (less than 50% resolution), or inferior MI
localized to 3 ECG leads probably should not be referred for
angiography. Likewise, it is doubtful that PCI of a branch artery
(diagonal or obtuse marginal branch) will change prognosis in
the absence of high-risk criteria noted above.
7. PCI After Fibrinolysis or for Patients Not
Undergoing Primary Reperfusion
As described in the 2004 STEMI Guidelines, PCI has been
Figure 3. Efficacy End Points for Rescue PCI Versus Conservativ
Early Revascularization to Limit Infarction trial; NNT, number need
Angioplasty versus Conservative Treatment or Repeat Thromboly
with Conservative Management of Patients with Early Failure of T
risk; and TAMI, Thrombolysis and Angioplasty in Myocardial Infarperformed immediately after successful fibrinolytic therapy,hours to days after successful fibrinolytic therapy, and days to
weeks after successful fibrinolytic therapy.15 With the in-
crease in use of an invasive strategy, consideration is now
also given to PCI in patients who did not undergo fibrinolysis,
and this concept is reflected in the decision of the writing
committee to rename this section to reflect considerations for
PCI both after fibrinolytic therapy and in STEMI patients
who do not undergo primary reperfusion. See the 2004
STEMI Guidelines, Section 6.3.1.6, and updates herein to
Sections 6.3.1.6.4.4 and 6.3.1.6.4.5 for additional discussions
bearing on PCI after fibrinolysis.
7.1. The Late Open Artery Hypothesis:
Clinical Outcomes
The open artery hypothesis suggested that late patency of an
infarct artery is associated with improved LV function,
increased electrical stability, and provision of collateral
vessels to other coronary beds for protection against future
events. The OAT (Occluded Artery Trial)12,13 tested the
hypothesis that routine PCI for total occlusion 3 to 28 days
apy. CI indicates confidence interval; MERLIN, Middlesbrough
treat; PCI, percutaneous coronary intervention; REACT, Rescue
l; RESCUE, Randomized Comparison of Rescue Angioplasty
olysis for Acute Anterior Myocardial Infarction trial; RR, relative
tudy. Reprinted with permission.62e Ther
ed to
sis triaafter MI would reduce the composite of death, reinfarction, or
myocar
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 Class IV heart failure. Stable patients (n2166) with an
occluded infarct artery after MI (about 20% of whom re-
ceived fibrinolytic therapy for the index event) were random-
ized to optimal medical therapy and PCI with stenting or
optimal medical therapy alone. The qualifying period of 3 to
28 days was based on calendar days; thus, the minimal time
from symptom onset to angiography was just over 24 hours.
Inclusion criteria included total occlusion of the infarct-
related artery with TIMI grade 0 or 1 antegrade flow and left
ventricular ejection fraction (LVEF) less than 50% or prox-
imal occlusion of a major epicardial artery with a large risk
region. Exclusion criteria included NYHA Class III or IV
heart failure, rest angina, serum creatinine greater than 2.5
mg per dL, left main or 3-vessel disease, clinical instabil-
ity, or severe inducible ischemia on stress testing if the
infarct zone was not akinetic or dyskinetic.12 The 4-year
cumulative end point was 17.2% in the PCI group and
15.6% in the medical therapy group (HR 1.16 [95% CI
0.92 to 1.45]; p0.2).13 Reinfarction rates tended to be
higher in the PCI group, which may have attenuated any
benefit in LV remodeling. There was no interaction be-
tween treatment effect and any subgroup variable.
7.2. The Late Open Artery Hypothesis:
Angiographic Outcomes
Preclinical studies have suggested that late opening of an
occluded infarct artery may reduce adverse LV remodeling
and preserve LV volumes. However, 5 previous clinical
studies in 363 patients have demonstrated inconsistent
improvement in LVEF or LV end-systolic and end-
diastolic volumes after PCI. The largest of these,
the DECOPI (DEsobstruction COronaire en Post-
Infarctus) trial, found a higher LVEF at 6 months with
PCI.65 TOSCA-2 (Total Occlusion Study of Canada)14
enrolled 381 stable patients in a mechanistic ancillary
study of OAT and had the same eligibility criteria.12,13 The
PCI procedure success rate was 92% and the complication
rate was 3%, although 9% had periprocedural MI as
measured by cardiac biomarkers. At 1 year, patency rates
(n332) were higher with PCI (83% vs. 25%; p less than
0.0001), but each group (n286) had equivalent improve-
ment in LVEF (4.2% vs. 3.5%; p0.47). There was modest
benefit of PCI in preventing LV dilation over 1 year in a
multivariate model, but only 42% had paired volume
determinations, so it is unclear whether this finding ex-
Table 7. Updates to Section 6.3.1.6.4.7: PCI After Successful Fib
2004 STEMI Guideline Recommendation 2007 ST
Routine PCI might be considered as part of an
invasive strategy after fibrinolytic therapy. (Level
of Evidence: B)
1. PCI of a hemodynamically signi
after STEMI may be considered
1. PCI of a totally occluded infarct
in asymptomatic patients with o
electrically stable and do not ha
PCI indicates percutaneous coronary intervention, and STEMI, ST-elevationtends to the whole cohort. The potential benefit of PCI inattenuating remodeling may have been decreased by
periprocedural MI and the high rate of beta blocker and
angiotensin-converting enzyme (ACE) inhibitor use. There
was no significant interaction between treatment effect and
time, infarct artery, or infarct size.
7.3. Conclusion
These studies demonstrate that elective PCI of an occluded
infarct artery 1 to 28 days after MI in stable patients had no
incremental benefit beyond optimal medical therapy with
aspirin, beta blockers, ACE inhibitors, and statins in preserv-
ing LV function and preventing subsequent cardiovascular
events (Table 7).
8. Ancillary Therapy
2004 STEMI Guidelines—Section 6.3.1.6.8.1. Anticoagulants
as Ancillary Therapy to Reperfusion Therapy
Since publication of the 2004 STEMI Guidelines,15 a
number of studies have provided data that inform the recom-
mendations on ancillary therapy to support reperfusion ther-
apy for STEMI. In recognition that many agents capable of
inhibiting the coagulation cascade may inhibit proteins other
than thrombin, the writing group decided to change the
nomenclature for this section. Therefore, the term anticoagu-
lants is used in place of the prior term antithrombins. Also,
although the material discussed below crosses several sub-
sections in the 2004 STEMI Guidelines (Sections
6.3.1.6.8.1.1 and 6.3.1.6.8.1.2), because of a number of
common issues, the writing group has elected to describe the
updates on anticoagulant therapy collectively in this section.
Unfractionated heparin (UFH) is commonly administered
to patients receiving fibrinolytic therapy. With limited evi-
dence supporting the benefits of prolonged infusions of UFH
and because of the progressive increase in the risk of
heparin-induced thrombocytopenia (both rapid- and delayed-
onset presentations),66,67 the 2004 STEMI Guidelines recom-
mended that infusions of UFH be given routinely for 48 hours
but be given for a longer period only in patients with an
ongoing indication for anticoagulation.15,68,69 Although no
new trials specifically focusing on UFH in STEMI were
reported, a number of studies have compared alternative
anticoagulant regimens with UFH or placebo. Importantly,
each study tested a strategy that involved administering the
new regimen (reviparin, fondaparinux, or enoxaparin) for the
is or for Patients Not Undergoing Primary Reperfusion
sed Update Recommendation Comments
nosis in a patent infarct artery greater than 24 hours
of an invasive strategy. (Level of Evidence: B)
Modified recommendation
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I
eater than 24 hours after STEMI is not recommended
o-vessel disease if they are hemodynamically and
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 current practice and longer than recommended in the 2004
STEMI Guidelines. In addition, some of the new anticoagu-
lant regimens used dosing schemes that were based on patient
weight, age, or both. With the exception of reviparin, the
details of the dosing schemes are noted in the recommenda-
tions above; the text below refers simply to the name of the
anticoagulant regimen. Major efficacy and safety observa-
tions from the main trial and important subgroups reported to
date are shown in Table 9.
The CREATE (Cardiovascular risk Reduction by Early
Anemia Treatment with Epoetin beta) trial was a randomized,
double-blind comparison of a strategy of low-molecular-
weight heparin (LMWH) reviparin versus placebo in 15 570
patients with STEMI enrolled in China and India70 Although
reviparin is not available for clinical use in North America,
the writing group felt that the data from the CREATE trial
were informative to clinicians and supported the data from
the trials discussed subsequently. The dosing regimen for
reviparin was as follows: for patients weighing less than 50
kg, subcutaneous injections of 3436 IU Ph Eur anti-Xa units
every 12 hours; for patients weighing 50 to 75 kg, subcuta-
neous injections of 5153 IU Ph Eur anti-Xa units every 12
Table 8. Updates to Section 6.3.1.6.8.1: Anticoagulants as Ancill
2004 STEMI
Guideline
Recommendation 2007 STEMI Focuse
1. Patients undergoing reperfusion with fibrinolytics should rece
Evidence: C) and preferably for the duration of the index hos
if anticoagulant therapy is given for more than 48 hours bec
UFH treatment). (Level of Evidence: A)
Anticoagulant regimens with established efficacy include:
a. UFH (initial intravenous bolus 60 U per kg [maximum 400
(maximum 1000 U per hour) initially, adjusted to maintain
(approximately 50 to 70 seconds) (Level of Evidence: C). (
duration of the infusion of UFH beyond 48 hours in the ab
infusions of UFH increase the risk of development of hepa
b. Enoxaparin (provided the serum creatinine is less than 2.5
than 75 years of age, an initial 30 mg intravenous bolus i
mg per kg every 12 hours; for patients at least 75 years
dose is reduced to 0.75 mg per kg every 12 hours. Regar
formula) during the course of treatment is estimated to be
per kg every 24 hours. Maintenance dosing with enoxapa
to 8 days. (Level of Evidence: A)
c. Fondaparinux (provided the serum creatinine is less than
subcutaneous injections of 2.5 mg once daily. Maintenanc
index hospitalization, up to 8 days. (Level of Evidence: B)
2. For patients undergoing PCI after having received an anticoa
followed:
a. For prior treatment with UFH, administer additional boluse
whether GP IIb/IIIa receptor antagonists have been admini
treated previously with UFH. (Level of Evidence: C)
b. For prior treatment with enoxaparin, if the last subcutaneo
enoxaparin should be given; if the last subcutaneous dose
of 0.3 mg per kg of enoxaparin should be given. (Level of
c. For prior treatment with fondaparinux, administer addition
activity taking into account whether GP IIb/IIIa receptor an
1. Because of the risk of catheter thrombosis, fondaparinux sho
additional anticoagulant with anti-IIa activity should be adminGP indicates glycoprotein; PCI, percutaneous coronary intervention; STEMI, ST-elevhours; and for patients weighing more than 75 kg, subcuta-
neous injections of 6871 IU Ph Eur anti-Xa units every 12
hours. Reviparin was continued for the duration of the index
hospitalization, up to 1 week. Fibrinolytic therapy (predom-
inantly non–fibrin-specific agents) was administered to 73%
of the CREATE trial population, and it was recommended
that the study drugs be started within 15 minutes of initiation
of fibrinolysis. A total of 76% of the trial population received
blinded study therapy for 7 days (see Table 9).
The OASIS-6 (Organization for the Assessment of Strate-
gies for Ischemic Syndromes) trial was an international,
randomized, double-blind comparison of fondaparinux, a
synthetic factor Xa inhibitor, versus control therapy (either
placebo or UFH) in 12 092 patients enrolled in 41 countries.7
Patients for whom the treating physician thought UFH was
not indicated (e.g., non–fibrin-specific fibrinolytic adminis-
tered) were enrolled in stratum I and received placebo in the
control arm; patients for whom the treating physician thought
UFH was indicated (e.g., fibrin-specific fibrinolytic adminis-
tered or primary PCI performed) were enrolled in stratum II
and received UFH in the control arm. The median duration of
fondaparinux therapy was 8 days in stratum I and 7 days in
erapy to Reperfusion Therapy
Recommendation Comments
I
oagulant therapy for a minimum of 48 hours (Level of
on, up to 8 days (regimens other than UFH are recommended
the risk of heparin-induced thrombocytopenia with prolonged
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 Table 9. Trials of Anticoagulants for STEMI
Trial (Drug) STEMI Cohorts Studied Efficacy Observations Safety Observations Transition to PCI
CREATE (reviparin)70
N  15 570
Fibrinolysis (N  11 355)
Primary PCI (N  949)
No reperfusion (N  3325)
Death/MI/Stroke (Day 7) Life-Threatening Bleeds
(Day 7)
Protocol recommended open-label
UFH54
Reviparin Placebo Reviparin Placebo
N  7780 N  7790
7 d: 9.6% 7 d: 11.0% 7 d: 0.9% 7 d: 0.4%
HR 0.87
95% CI 0.79 to 0.96
HR 2.49
95% CI 1.61 to 3.87
30 d: 11.8% 30 d: 13.6%
HR 0.87
95% CI 0.79 to 0.95
Reperfused Cohort
Reviparin Placebo Reviparin Placebo
30 d: 11.0% 30 d: 12.3% 30 d: 1.1% 30 d: 0.4%
HR 0.90
95% CI 0.81 to 1.01
HR N/A
Nonreperfused Cohort
Reviparin Placebo Reviparin Placebo
30 d: 15.0% 30 d: 18.3% 30 d: 0.1% 30 d: 0.1%
HR 0.79
95% CI 0.65 to 0.95
HR N/A
OASIS-6
(fondaparinux)7,83a,83b
N  12 092
Fibrinolysis (N  5436)
(Non–fibrin-specific 4561;
fibrin-specific 875)
Primary PCI (N  3789)
No reperfusion (N  2867)
Death/MI (Day 30) Severe Hemorrhage (Day 9) UFH (guided by ACT) for control
subjects in Stratum II and
supplemental 2.5 to 5.0 mg IV
bolus of fondaparinux (depending
on whether subject received open-
label UFH and/or GP IIb/IIIa
inhibitors before randomization) in
the fondaparinux group. Drugs
were administered in double-blind
fashion during PCI6.
Fondaparinux Control Fondaparinux Control
N  6036 N  6056 N  6036 N  6056
9.7% 11.2% 1.0% 1.3%
HR 0.86
95% CI 0.77 to 0.96
HR 0.77
95% CI 0.55 to 1.08
Stratum I
Severe Hemorrhage (Day 9)
Fondaparinux Placebo Fondaparinux Placebo
11.2% 14.0% 1.0% 1.6%
HR 0.79
95% CI 0.68 to 0.92
HR 0.63
95% CI 0.40 to 1.02
Stratum II
Severe Hemorrhage (Day 9)
Fondaparinux UFH Fondaparinux UFH
8.3% 8.7% 1.1% 1.1%
HR 0.96
95% CI 0.81 to 1.13
HR 0.95
95% CI 0.59 to 1.52
Non–Fibrin-Specific Lytics
Severe Hemorrhage (Day 30)
Fondaparinux Placebo Fondaparinux Placebo
10.7% 13.8% 1.2% 2.0%
HR 0.76
95% CI 0.64 to 0.90
HR 0.60
95% CI 0.37 to 0.97
Fibrin-Specific Lytics
Severe Hemorrhage (Day 30)
Fondaparinux UFH Fondaparinux UFH
12.1% 12.1% 1.7% 2.5%
HR 1.01
95% CI 0.69 to 1.48
HR 0.67
95% CI 0.26 to 1.73
Primary PCI
Severe Hemorrhage (Day 9)
Fondaparinux UFH Fondaparinux UFH
6.1% 5.1% 2.2% 1.7%
HR 1.20
95% CI 0.91 to 1.57
HR 1.30
95% CI 0.81 to 2.08
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 Table 9. Continued
Trial (Drug) STEMI Cohorts Studied Efficacy Observations Safety Observations Transition to PCI
OASIS-6 (Continued) No Reperfusion
Stratum I Stratum I/Stratum II
Severe Hemorrhage (Day 30)
Fondaparinux Placebo Fondaparinux Control
N  1458 N  1409
12.9% 14.4% 1.5% 2.1%
HR 0.88
95% CI 0.65 to 1.19
HR 0.76
95% CI 0.42 to 1.36
Stratum II
Fondaparinux UFH
11.7% 15.5%
HR 0.74
95% CI 0.57 to 0.97
ExTRACT-TIMI 25
(enoxaparin)
N  20 5066,73,83c,83d
Alteplase (N  11 175)
Tenecteplase (N  3986)
Reteplase (N  1122)
Streptokinase (N  4139)
None (N  57)
Death/MI (Day 30) Severe Hemorrhage (Day 30) UFH (guided by ACT) in subjects
allocated to UFH and supplemental
IV bolus of 0.3 mg per kg
enoxaparin in subjects allocated to
enoxaparin if last subcutaneous
dose was 8 to 12 hours earlier.
Drugs administered in double-blind
fashion during PCI56,57.
Enoxaparin UFH Enoxaparin UFH
N  10 256 N  10 223 N  10 176 N  10 151
9.9% 12.0% 2.1% 1.4%
RR 0.83
95% CI 0.77 to 0.90
RR 1.53
95% CI 1.23 to 1.89
Age Less Than 75 Years (all lytics)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
7.9% 9.9% 1.9% 1.1%
RR 0.80
95% CI 0.72 to 0.87
RR 1.67
95% CI 1.31 to 2.13
Age 75 Years or Older (all lytics)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
24.8% 26.3% 3.3% 2.9%
RR 0.94
95% CI 0.82 to 1.08
RR 1.15
95% CI 0.74 to 1.78
Fibrin-Specific Lytics (all ages)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
9.8% 12.0% 2.0% 1.2%
OR adj 0.78
95% CI 0.70 to 0.87
RR 1.89
95% CI 1.43 to 2.51
Non–Fibrin-Specific Lytics (all ages)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
10.2% 11.8% 2.4% 2.0%
OR adj 0.83
95% CI 0.66 to 1.04
RR 1.38
95% CI 0.88 to 2.17
PCI postlysis (rescue, urgent,
elective)
N  4676
PCI Postlysis
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
10.7% 13.8% 1.4% 1.6%
RR 0.77
95% CI 0.66 to 0.90
RR 0.87
95% CI 0.55 to 1.39
ACT indicates activated clotting time; adj, adjusted; CI, confidence interval; CREATE, Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta;
ExTRACT-TIMI 25, Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction; GP, glycoprotein; HR,
hazard ratio; kg, kilogram; MI, myocardial infarction; N, number; N/A, not available; OASIS, Organization to Assess Strategies for Ischemic Syndromes; OR, odds ratio;
PCI, percutaneous coronary intervention; RR, relative risk; STEMI, ST-elevation myocardial infarction; and UFH, unfractionated heparin.
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 stratum II (compared with 45 hours of UFH). Within the trial
population, 2867 patients (23.7%) did not receive any reper-
fusion therapy and, depending on physician preference, were
enrolled in either stratum I or II (see Table 9).
The ExTRACT-TIMI 25 trial was an international, double-
blind comparison of a strategy of enoxaparin versus UFH in
20 506 patients enrolled in 48 countries who presented within
6 hours after the onset of STEMI and for whom fibrinolytic
therapy was planned.6 Because prior trials reported that
bleeding with enoxaparin was increased in elderly patients, a
novel dosing regimen was devised for patients 75 years of age
or older, and strict attention was paid to dose reduction in
patients with significantly impaired renal function to mini-
mize the accumulation of anti-Xa activity.71,72 The median
duration of treatment was 7 days with enoxaparin and 2 days
for UFH (see Table 9).
Some patients who receive pharmacological reperfusion
with a fibrinolytic are referred for PCI. Consideration must be
given to the anticoagulant regimen to support PCI in the face
of preceding (upstream) anticoagulant therapy. The
CREATE, OASIS-6, and ExTRACT-TIMI 25 trials took
different approaches to the selection of anticoagulants to
support PCI. Both CREATE and OASIS-6 included subsets
of patients undergoing primary PCI; ExTRACT-TIMI 25 did
not study patients undergoing primary PCI. In CREATE,
patients in both the reviparin and placebo groups received
open-label UFH at the time of PCI. In OASIS-6, the protocol
recommended an IV bolus of fondaparinux (2.5 to 5.0 mg,
depending on whether the patient received open-label UFH
and/or GP IIb/IIIa inhibitors before randomization) (see
Table 9). The number of patients in whom catheter thrombo-
sis was observed was 0 in the UFH group and 22 in the
fondaparinux group (p less than 0.001).7 When the subset of
patients who received both open-label UFH and fondaparinux
was analyzed, the number of catheter thromboses was 0 in the
UFH group and 2 in the fondaparinux group.
In ExTRACT-TIMI 25, patients were maintained on the
allocated anticoagulant as they moved from the medical to
PCI phase of treatment (n2178) or received open-label
anticoagulant at the treating physician’s discretion if per-
formed after 8 days (n2498). Among the patients allocated
to enoxaparin, a dose of 0.3 mg per kg was administered
intravenously if the last subcutaneous dose was 8 to 12 hours
earlier, whereas no additional enoxaparin was administered if the
last subcutaneous dose was administered within the prior 8
hours. UFH was dosed according to the activated clotting time
(ACT), using a target of 200 seconds for patients receiving a GP
IIb/IIIa inhibitor and 250 seconds for those not receiving a GP
IIb/IIIa inhibitor.73 The main observations (Table 9) were the
same whether the results were analyzed by intention to treat or
by the actual anticoagulant received during the procedure
(blinded study or open-label anticoagulant if PCI was performed
after Day 8).73
8.1. Conclusion
The writing group felt that several important messages
emerged from the CREATE, OASIS-6, and ExTRACT-TIMI
25 trials, and these are reflected in the updated recommenda-
tions (Table 8) and summarized in Table 10. Anticoagulanttherapy is beneficial in patients with STEMI, and there is
benefit in more prolonged anticoagulant therapy (duration of
index hospitalization) in patients receiving fibrinolytics, as
seen in the comparisons of reviparin versus placebo
(CREATE), fondaparinux versus placebo (stratum I in
OASIS-6), and enoxaparin versus UFH (ExTRACT-TIMI
25). The mechanism of benefit from a more prolonged
anticoagulant regimen is probably multifactorial and includes
a longer exposure to anticoagulants to prevent rethrombosis
of the infarct artery and prevention of the rebound increase in
events seen after abrupt discontinuation of UFH infusions.
Concern was raised about a rebound increase in events after
abrupt discontinuation of UFH infusions in patients with
UA/NSTEMI,74 but this also appears to occur in patients with
STEMI.6 The optimum method of terminating treatment with
UFH has not been rigorously established for patients with
either UA/NSTEMI or STEMI, but it is common clinical
practice to simply discontinue UFH infusions. Finally, when
the new anticoagulant regimens are compared with UFH as
an active control, the greater degree of inhibition of the
proximal portion of the coagulation cascade may lead to a
greater reduction in thrombin generation.
Of note, reviparin, enoxaparin, and fondaparinux all in-
volve, at least in part, clearance via the renal route. Hence, the
potential exists for accumulation of anti-Xa activity with
increasing degrees of renal failure. On the basis of available
data, recommendations have been formulated for baseline
creatinine cut points when a patient is considered for one of
the new regimens. Also, estimation of creatinine clearance
should be calculated via the Cockcroft-Gault formula rather
than the Modification of Diet and Renal Disease (MDRD)
equation, because the former has been used to modify dosing
in clinical trials.75 The writing group endorses further re-
search into the optimum anticoagulant regimen in patients
with moderate degrees of renal dysfunction. This group has
not been studied extensively and may be at an increased risk
of bleeding, which has been seen in contemporary dosing
regimens. The group also recommends head-to-head compar-
ative studies to evaluate newer anticoagulant drugs (e.g.,
fondaparinux, enoxaparin, bivalirudin) to assess optimal an-
ticoagulant therapy in patients with STEMI; such studies
could provide more clinically useful information than com-
parisons against UFH or no anticoagulant.
When added to previous data, the benefits of anticoagula-
tion therapy started concurrently with non–fibrin-specific
fibrinolytic agents (e.g., streptokinase) seen with all 3 of the
new anticoagulation regimens led the writing group to rec-
ommend the use of an anticoagulant across the spectrum of
fibrinolytic agents in common clinical use.6,7,70,76,77
When moving to PCI after fibrinolytic therapy, those
patients who received upstream UFH or enoxaparin can
continue to receive those anticoagulants in a seamless fashion
(i.e., without crossover to another agent) using the dosing
regimens listed in the recommendations.73 On the basis of the
reports of catheter thrombosis with fondaparinux alone dur-
ing primary PCI in OASIS-6 and the experience with
fondaparinux in the OASIS-5 trial,78 the writing group
thought fondaparinux should not be used as the sole antico-
agulant during PCI but should be coupled with an additional
cardial
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 agent that has anti-IIa activity to ameliorate the risk of
catheter complications. Although bivalirudin and UFH are
potential options for supplemental anticoagulation with
fondaparinux, the available experience, albeit limited, is
largely with UFH. The only available data from the CREATE
trial that bear on this point are with UFH.
Given the complexities of the characteristics of the indi-
vidual agents and their actions on the coagulation cascade,
clinicians are cautioned about extrapolating any of the obser-
vations with agents discussed in this update to other antico-
agulant regimens. In particular, as noted by the FDA,
LMWHs are sufficiently distinct that they should be evaluated
individually rather than considered as a class of interchange-
able agents.79
The writing group also advises clinicians against drawing
comparisons between the new anticoagulant regimens across
trials because of the nonrandomized nature of such compar-
isons and the inability to ensure comparability of baseline
characteristics for the populations in the trials. Finally, the
writing group strongly cautions clinicians against overinter-
pretation of subgroup analyses in the trials listed in Table 9
(e.g., reperfusion with either fibrinolytics or PCI versus no
reperfusion; reperfusion with various categories of fibrinolyt-
ics; and comparison of the new anticoagulant strategy versus
placebo or UFH). Subgroup comparisons are less statistically
robust than the main trial results because of their nonrandom-
ized nature, the lack of statistical power to discern true
differences in treatment effects, and the need to account for
multiple comparisons. Nonsignificant interaction tests should
not be used to definitively assert a lack of heterogeneity of
treatment effects across subgroups, as such analyses are
relatively weak statistical tests, especially in the case of small
sample sizes in subgroups.80–83 In the case of the data in
Table 9, an additional layer of complexity—a mixture of
comparisons between placebo and an active comparator
(UFH)—was introduced. The approach taken in Table 9 was
Table 10. Summary of Observations From Trials of Anticoagulan
Anticoagulant Efficacy (through 30 days)
Reviparin Fibrinolysis: probably superior to placebo* Increased risk
No reperfusion: probably superior to placebo*
Fondaparinux Fibrinolysis: appears superior to control therapy
(placebo/UFH). Relative benefit versus placebo
and UFH separately cannot be reliably
determined from available data.*
Trend toward
serious bleeds
Primary PCI: when used alone, no advantage
over UFH and trend toward worse outcome (see
“Use During PCI”)
No reperfusion: appears superior to control
therapy (placebo/UFH). Relative benefit versus
placebo and UFH separately cannot be reliably
determined from available data.*
Enoxaparin Fibrinolysis: appears superior to UFH Increased risk
*See text for further discussion and subgroup analysis.
†Definitions of significant bleeds varied among trials. Consult original refer
PCI indicates percutaneous coronary intervention; STEMI, ST-elevation myoto provide the point estimate and 95% CI of the treatmenteffect in various subgroups to allow readers to see the range
of possible treatment effects.82
The writing group encourages randomization of additional
patients in future trials to clarify a number of questions, such
as 1) the benefits of reviparin compared with UFH in patients
receiving fibrin-specific fibrinolytics or undergoing PCI, 2)
the relative benefits of fondaparinux compared with UFH in
patients receiving non–fibrin-specific and fibrin-specific fi-
brinolytics, as well as those patients not undergoing reperfu-
sion, and 3) the relative benefits of enoxaparin compared with
UFH in patients undergoing primary PCI and those not
receiving reperfusion therapy.
9. Thienopyridines
The 2004 STEMI Guidelines made no specific recommendation
related to dual antiplatelet therapy with clopidogrel plus low-
dose aspirin for a broad population of patients at high risk for
atherothrombotic events. Clopidogrel has previously been
shown to benefit patients with documented atherosclerosis (re-
cent MI, recent stroke, established peripheral arterial disease,
PCI, and NSTEMI). Since publication of the 2004 STEMI
Guidelines, 2 trials have been reported that provide data sup-
porting expansion of the use of clopidogrel to the STEMI end of
the acute coronary syndrome spectrum.84
The COMMIT-CCS-2 study randomized 45 852 patients
within 24 hours of suspected MI at 1250 hospitals in China to
75 mg of clopidogrel daily (without a loading dose) or
placebo in addition to 162 mg of aspirin daily.3 In the trial
population, 93% had ST-segment elevation or bundle-branch
block, 7% had ST-segment depression, and 54% were treated
with fibrinolysis (predominantly urokinase). There was no
upper age limit. The mean age was 61 years; 26% of patients
were 70 years of age or older. Twenty-eight percent were
women. The study drug treatment was to continue until
hospital discharge or up to 4 weeks; mean treatment duration
STEMI
Use During PCI
s bleeds† No data on reviparin alone during PCI. Additional anticoagulant with
anti-IIa activity, such as UFH or bivalirudin, recommended.
d risk of Increased risk of catheter thrombosis when fondaparinux used
alone. Additional anticoagulant with anti-IIa activity, such as UFH or
bivalirudin, recommended.
s bleeds† Enoxaparin can be used to support PCI after fibrinolysis.
No additional anticoagulant needed.
r details.
infarction; and UFH, unfractionated heparin.ts for
Safety
of seriou
decrease
†
of seriou
ences fowas 14.9 days (25th, 50th, and 75th percentiles: 9, 14, and 21
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 days, respectively). The composite primary end point of
death, reinfarction, or stroke was reduced from 10.1% in the
placebo group to 9.2% in the clopidogrel group (OR 0.91
[95% CI 0.86 to 0.97]; p0.002). Benefit with clopidogrel
tended to be seen in the subgroups of patients who did and did
not receive fibrinolytic therapy. The co-primary end point of
all-cause mortality was reduced from 8.1% in the placebo
group to 7.5% in the clopidogrel group (OR 0.93 [95% CI
0.87 to 0.99]; p0.03; NNT167). The rate of cerebral and
major noncerebral bleeding was 0.55% in the placebo group
and 0.58% in the clopidogrel group (p0.59).
The CLARITY-TIMI 28 (Clopidogrel as Adjunctive
Reperfusion Therapy – Thrombolysis in Myocardial Infarc-
tion 28) study randomized 3491 patients (18 to 75 years of
age) receiving fibrinolytic therapy within 12 hours of STEMI
to clopidogrel (300 mg oral loading dose; 75 mg oral daily
maintenance dose) or placebo.9 The primary composite effi-
cacy end point of an occluded infarct artery on angiography
or death or recurrent MI before angiography (between 48 and
192 hours after the start of study medication) occurred in
21.7% of the placebo group and 15.0% of the clopidogrel
group (OR 0.64 [95% CI 0.53 to 0.76]; p less than 0.001). The
benefit of clopidogrel was driven largely by the reduction in
rate of an occluded infarct artery, which appears to have been
accomplished by preventing infarct-related reocclusion rather
than by facilitating early reperfusion.85 The rate of TIMI
major bleeding through 30 days was 1.7% in the placebo
group and 1.9% in the clopidogrel group (p0.80). When
interpreting the safety of clopidogrel, especially in the face of
a loading dose of 300 mg, it is important to note that subjects
were excluded from CLARITY-TIMI 28 if they had received
more than 4000 U of UFH before randomization.
The patients in the clopidogrel arm of CLARITY-TIMI 28
who underwent PCI constitute a group who were pretreated
with clopidogrel and provide a comparison with those in the
Table 11. Updates to Section 6.3.1.6.8.2.2: Thienopyridines
2004 STEMI Guideline
Recommendation 2007 STEMI F
1. Clopidogrel 75 mg per day orally should be
they undergo reperfusion with fibrinolytic th
Evidence: A) Treatment with clopidogrel sh
In patients taking clopidogrel for
whom CABG is planned, the drug
should be withheld for at least 5
days and preferably for 7 days
unless the urgency for
revascularization outweighs the
risks of excess bleeding. (Level of
Evidence: B)
2. In patients taking clopidogrel in whom CAB
and preferably for 7 days unless the urgen
(Level of Evidence: B)
1. In patients less than 75 years of age who
therapy, it is reasonable to administer an o
(No data are available to guide decision ma
age or older.)
2. Long-term maintenance therapy (e.g., 1 ye
STEMI patients regardless of whether they
reperfusion therapy. (Level of Evidence: C)CABG indicates coronary artery bypass graft, and STEMI, ST-elevation myocardialplacebo arm who underwent PCI without pretreatment.86 The
composite end point of cardiovascular death, recurrent MI, or
stroke from PCI to 30 days after enrollment was 6.2% in the
non-pretreatment group and 3.6% in the pretreatment group
(OR 0.54 [95% CI 0.35 to 0.85]; p0.008).86 There was no
significant difference in the rates of the composite of TIMI
major or minor bleeding in the pretreatment versus non-
pretreatment groups (2.0% vs. 1.9%; p greater than 0.99).
9.1. Conclusion
The writing group felt that the COMMIT-CCS-2 and
CLARITY-TIMI 28 trials provided evidence for benefit of
adding clopidogrel to aspirin in patients undergoing fibrino-
lytic therapy (Table 11). The COMMIT-CCS-2 trial also
supported the use of clopidogrel in patients who were not
receiving reperfusion therapy. Although the available data
suggest that the oral maintenance dose should be 75 mg daily,
uncertainty exists about the efficacy and safety of adding a
loading dose to elderly patients (more than 75 years of age),
especially when they receive a fibrinolytic. Thus, the writing
group does not recommend a loading dose in the elderly who
receive a fibrinolytic and endorses further research to define
the optimum clopidogrel regimen in the elderly. On the basis
of the CLARITY-TIMI 28 study, it appears that the admin-
istration of clopidogrel at the time of initial fibrinolytic
therapy is of benefit when PCI is performed subsequently. No
data are available from clinical trials regarding long-term
clopidogrel treatment in STEMI patients. Extrapolating from
experience in patients with UA/NSTEMI, as well as those
patients undergoing coronary stenting, the writing committee
felt that long-term therapy with clopidogrel (e.g., 1 year) can
be useful in patients with STEMI (Class IIa; Level of
Evidence: C) (Table 11). Clinicians should consult Figure 37
in Section 7.12.11 of the 2004 STEMI Guidelines for guid-
pdate Recommendation Comments
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 ance when the patient has concurrent indications for oral
anticoagulation.15
In August 2006, the FDA approved the use of clopidogrel
for the treatment of patients with STEMI to reduce the rate of
death from any cause and the rate of the combined end point
of death, reinfarction, or stroke.87
10. Anticoagulants
In the 2004 STEMI Guidelines, anticoagulant therapy with
UFH was recommended for patients not receiving reperfusion
with the goal of reducing mortality and reinfarction rates. In
patients with UA/NSTEMI, treatment with LMWH is recom-
mended with a similar goal, as well as for prevention of
episodes of recurrent ischemia. Since publication of the 2004
STEMI Guidelines, 2 trials (CREATE and OASIS-6) have
extended the database on which such recommendations were
formulated by providing evidence of the benefit of anticoag-
ulant therapy in STEMI patients who do not receive reperfu-
sion therapy (see Tables 9 and 10).
Although 2 contemporary trials provided internally consistent
findings of benefit of prolonged anticoagulant therapy (duration
of the index hospitalization) in patients not receiving reperfusion
therapy, the nonreperfusion groups were subgroups that repre-
sented only about 22% of the trial populations. Also, the patients
were enrolled largely at sites that may have had different practice
patterns than in North America, and there is uncertainty about
the exact magnitude of the treatment effect of anticoagulants in
the absence of more widespread use of clopidogrel. Because of
these issues, the writing group concluded that a Class IIa, Level
of Evidence: B recommendation should be assigned (Table 12).
Convenient strategies that may be used include those with
Table 12. Updates to Section 7.4.5: Anticoagulants
2004 STEMI Guideline Recommendation
It is reasonable that STEMI patients who are not undergoing
reperfusion therapy and who do not have a contraindication to
anticoagulation be treated with IV or subcutaneous UFH or with
subcutaneous LMWH for at least 48 hours. In patients whose
clinical condition necessitates prolonged bedrest and/or minimized
activity, it is reasonable that treatment be continued until the
patient is ambulatory. (Level of Evidence: C)
1. It is reas
reperfusi
UFH regi
days. (Le
used inc
fondapar
regimens
Section 6
IV indicates intravenous; LMWH, low-molecular-weight heparin; LOE, level ofLOE indicates level of evidence, and STEMI, ST-elevation myocardial infarction.Evidence: B) using the same dosing regimens as those for
patients who receive fibrinolytic therapy (Table 12). See the
2004 STEMI Guidelines, Section 8 (updates to Section
6.3.1.6.8.1).15
11. Invasive Evaluation
The committee has revised the recommendations for invasive
evaluation (Table 13).
12. Secondary Prevention
Table 14 contains revised recommendations adapted from the 2006
AHA/ACC Guidelines for Secondary Prevention for Patients with
Coronary and Other Atherosclerotic Vascular Disease.11 This table
replaces Table 32 from the 2004 STEMI Guidelines.15 Classes of
recommendation and a corresponding level of evidence have been
added for all recommendations. New recommendations for clopi-
dogrel have been added to the section on antiplatelet agents/
anticoagulants: clopidogrel 75 mg per day should be added to
aspirin in patients with STEMI for at least 14 days whether patients
undergo reperfusion with fibrinolysis or do not receive reperfusion
therapy (i.e., all post-PCI nonstented STEMI patients). The benefits
of clopidogrel are likely to continue with longer duration of
treatment, although there are no data from randomized controlled
trials beyond 30 days. This section has also been modified slightly
to reflect the recent evidence on aspirin dosage for patients who
have undergone PCI with stent placement.
Other changes since the 2001 AHA/ACC Secondary Pre-
vention Guidelines88 include the addition of recommended
daily physical activity, a recommendation for lowered low-
density lipoprotein cholesterol, and a new recommendation
MI Focused Update Recommendation Comments
r patients with STEMI who do not undergo
y to be treated with anticoagulant therapy (non-
the duration of the index hospitalization, up to 8
idence: B) Convenient strategies that can be
e with LMWH (Level of Evidence: C) or
el of Evidence: B) using the same dosing
atients who receive fibrinolytic therapy. See
1.
Modified recommendation
(changed LOE and text)
e; STEMI, ST-elevation myocardial infarction; and UFH, unfractionated heparin.LMWH (Level of Evidence: C) or fondaparinux (Level of for an annual influenza vaccination.
Table 13. Updates to Section 7.11.6: Invasive Evaluation
2004 STEMI Guideline Recommendation 2007 STEMI Focused Update Recommendation Comments
Class IIb
Catheterization and revascularization may be considered as part of a
strategy of routine coronary arteriography for risk assessment after
fibrinolytic therapy. (Level of Evidence: B)
1. Coronary arteriography may be considered as part of an invasive
strategy for risk assessment after fibrinolytic therapy (Level of
Evidence: B) or for patients not undergoing primary reperfusion. (Level
of Evidence: C)
Modified recommendation
(changed LOE and text)2007 STE
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 Table 14. Secondary Prevention for Patients With Coronary and Other Vascular Disease
2004 STEMI Guideline Recommendations 2007 STEMI Focused Update Recommendations
2007 COR
and LOE Comments
Smoking
2007 Goal: Complete cessation, no exposure to environmental tobacco smoke
Assess tobacco use. 1. Status of tobacco use should be asked about at every visit. I (B) Modified recommendation
(changed text)
Strongly encourage patient and family to stop
smoking and to avoid secondhand smoke.
2. Every tobacco user and family members who smoke should be advised to
quit at every visit.
I (B) Modified recommendation
(changed text)
3. The tobacco user’s willingness to quit should be assessed. I (B) New recommendation
Provide counseling, pharmacological therapy
(including nicotine replacement and bupropion), and
formal smoking cessation programs as appropriate.
(See Section 7.12.4 in the 2004 STEMI Guideline
for further discussion.)
4. The tobacco user should be assisted by counseling and developing a plan
for quitting.
I (B) Modified recommendation
(changed text)
5. Follow-up, referral to special programs, or pharmacotherapy (including
nicotine replacement and pharmacological treatment) should be arranged.
I (B) Modified recommendation
(changed text)
6. Exposure to environmental tobacco smoke at work and home should be
avoided.
I (B) New recommendation
Blood Pressure Control:
2007 Goal: Less than 140/90 mm Hg or less than 130/80 if patient has diabetes or chronic kidney disease
If blood pressure is 120/80 mm Hg or greater,
initiate lifestyle modification (weight control,
physical activity, alcohol moderation, moderate
sodium restriction, and emphasis on fruits,
vegetables, and low-fat dairy products) in all
patients.
1. For patients with blood pressure greater than or equal to 140/90 mm Hg
(or greater than or equal to 130/80 mm Hg for patients with diabetes or
chronic kidney disease), it is recommended to initiate or maintain lifestyle
modification—weight control; increased physical activity; alcohol
moderation; sodium reduction; and emphasis on increased consumption of
fresh fruits, vegetables, and low-fat dairy products.
I (B) Modified recommendation
(changed text)
If blood pressure is 140/90 mm Hg or greater, or
130/80 mm Hg or greater for individuals with
chronic kidney disease or diabetes, add blood
pressure–reducing medications,* emphasizing the
use of beta blockers and inhibitors of the renin-
angiotensin-aldosterone system. (See Sections
7.12.6, 7.12.7, and 7.12.8 in 2004 STEMI
Guideline.)15
2. For patients with blood pressure greater than or equal to 140/90 mm Hg
(or greater than or equal to 130/80 mm Hg for patients with diabetes or
chronic kidney disease), it is useful as tolerated, to add blood pressure
medication, treating initially with beta blockers and/or ACE inhibitors, with
the addition of other drugs such as thiazides as needed to achieve goal
blood pressure.
I (A) Modified recommendation
(changed text)
Lipid Management
2007 Goal: LDL-C substantially less than 100 mg per dL
(If triglycerides are greater than or equal to 200 mg per dL, non–HDL-C should be less than 130 mg per dL†.)
Start dietary therapy in all patients (less than 7% of
total calories as saturated fat and less than 200
mg/d cholesterol).
1. Starting dietary therapy is recommended for all patients. Reduce intake of
saturated fats (to less than 7% of total calories), trans fatty acids, and
cholesterol (to less than 200 mg per day).
I (B) Modified recommendation
(changed text)
2. Adding plant stanol/sterols (2 g per day) and/or viscous fiber (greater than
10 g per day) is reasonable to further lower LDL-C.
IIa (A) New recommendation
Promote physical activity and weight management. 3. Promotion of daily physical activity and weight management is
recommended.
I (B) Modified recommendation
(changed text)
Encourage increased consumption of omega-3 fatty
acids.
4. It may be reasonable to encourage increased consumption of omega-3
fatty acids in the form of fish‡ or in capsules (1 g per day) for risk
reduction. For treatment of elevated triglycerides, higher doses are usually
necessary for risk reduction.
IIb (B) Modified recommendation
(changed text)
Assess fasting lipid profile in all patients, preferably
within 24 h of STEMI. Add drug therapy according
to the following guide. (See Section 7.12.2 in the
STEMI 2004 Guideline.)
5. A fasting lipid profile should be assessed in all patients and within 24
hours of hospitalization for those with an acute cardiovascular or coronary
event. For hospitalized patients, initiation of lipid-lowering medication is
indicated as recommended below before discharge according to the
following schedule:
I (A) Modified recommendation
(changed text)
LDL-C less than 100 mg/dL (baseline or on
treatment), statins should be used to lower LDL-C.
● LDL-C should be less than 100 mg per dL. I (A) Modified recommendation
(changed text)
● Further reduction of LDL-C to less than 70 mg per dL is reasonable. IIa (A) New recommendation
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 Table 14. Continued
2004 STEMI Recommendations 2007 STEMI Recommendations
2007 COR
and LOE Comments
LDL-C greater than or equal to 100 mg/dL (baseline
or on treatment), intensify LDL-C-lowering therapy
with drug treatment, giving preference to statins.
● If baseline LDL-C is greater than or equal to 100 mg per dL, LDL-
lowering drug therapy§ should be initiated.
I (A) Modified recommendation
(changed text)
● If on-treatment LDL-C is greater than or equal to 100 mg per dL,
intensifying LDL-lowering drug therapy (may require LDL-lowering drug
combination) is recommended.
I (A) Modified recommendation
(changed text)
● If baseline LDL-C is 70 to 100 mg per dL, it is reasonable to treat to
LDL-C less than 70 mg per dL.
IIa (B) New recommendation
If triglycerides are greater than or equal to 150
mg/dL or HDL-C is less than 40 mg/dL, emphasize
weight management and physical activity. Advise
smoking cessation.
● If triglycerides are greater than or equal to 150 mg per dL or HDL-C is
less than 40 mg per dL, weight management, physical activity, and
smoking cessation should be emphasized.
I (B) Modified recommendation
(changed text)
If triglycerides are 200 to 499 mg/dL after LDL-C–
lowering therapy¶, consider adding fibrate or
niacin.**
● If triglycerides are 200 to 499 mg per dL,†† non–HDL-C target should be
less than 130 mg per dL.
I (B) Modified recommendation
(changed text)
● If triglycerides are 200 to 499 mg per dL,†† further reduction of non–
HDL-C to less than 100 mg per dL is reasonable.
IIa (B) New recommendation
6. Therapeutic options to reduce non–HDL-C include:
● More intense LDL-C–lowering therapy is indicated. I (B) New recommendation
● Niacin** (after LDL-C–lowering therapy) can be beneficial. IIa (B) Modified recommendation
(changed text)
● Fibrate therapy‡‡ (after LDL-C–lowering therapy) can be beneficial. IIa (B) Modified recommendation
(changed text)
If triglycerides are greater than or equal to 500
mg/dL:**‡‡
Consider fibrate or niacin‡‡ before LDL-C–lowering
therapy.**‡‡
Consider omega-3 fatty acids as adjunct for high
triglycerides. (See Section 7.12.2 in the 2004
STEMI Guideline.)
7. If triglycerides are greater than or equal to 500 mg per dL,††§§
therapeutic options indicated and useful to prevent pancreatitis are
fibrate‡‡ or niacin** before LDL-lowering therapy; and treat LDL-C to goal
after triglyceride-lowering therapy. Achieving non–HDL-C less than 130 mg
per dL is recommended.
I (C) Modified recommendation
(changed text)
Physical Activity
Goal: 30 minutes, 7 days per week (minimum 5 days per week)
Cardiac rehabilitation programs are recommended
for patients with STEMI, particularly those with
multiple modifiable risk factors and/or those
moderate- to high-risk patients in whom supervised
exercise training is warranted. (See Sections
7.12.12 and 8.2 in the 2004 STEMI Guideline.)
1. Advising medically supervised programs (cardiac rehabilitation) for high-risk
patients (e.g., recent acute coronary syndrome or revascularization, HF) is
recommended.
I (B) Modified recommendation
(changed text)
Assess risk, preferably with exercise test, to guide
prescription.
2. For all patients, it is recommended that risk be assessed with a physical
activity history and/or an exercise test to guide prescription.
I (B) Modified recommendation
(changed text)
Encourage minimum of 30 to 60 min of activity,
preferably daily but at least 3 or 4 times weekly
(walking, jogging, cycling, or other aerobic activity)
supplemented by an increase in daily lifestyle
activities (e.g., walking breaks at work, gardening,
household work).
3. For all patients, encouraging 30 to 60 minutes of moderate-intensity
aerobic activity is recommended, such as brisk walking on
most—preferably all—days of the week, supplemented by an increase in
daily lifestyle activities (e.g., walking breaks at work, gardening, and
household work).
I (B) Modified recommendation
(changed text)
4. Encouraging resistance training 2 days per week may be reasonable. IIb (C) New recommendation
Weight Management
Goal: BMI: 18.5 to 24.9 kg/m2
Waist circumference: Men less than 40 inches (102 cm), women less than 35 inches (89 cm)
Calculate BMI and measure waist circumference as
part of evaluation. Monitor response of BMI and
waist circumference to therapy.
1. It is useful to assess BMI and/or waist circumference on each visit and
consistently encourage weight maintenance/reduction through an
appropriate balance of physical activity, caloric intake, and formal
behavioral programs when indicated to maintain/achieve a BMI between
18.5 and 24.9 kg/m2.
I (B) Modified recommendation
(changed text)
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 Table 14. Continued
2004 STEMI Recommendations 2007 STEMI Recommendations
2007 COR
and LOE Comments
Start weight management and physical activity as
appropriate. Desirable BMI range is 18.5 to 24.9
kg/m2.
2. The initial goal of weight loss therapy should be to reduce body weight by
approximately 10% from baseline. With success, further weight loss can
be attempted if indicated through further assessment.
I (B) Modified recommendation
(changed text)
If waist circumference is greater than or equal to
35 inches in women or greater than or equal to 40
inches in men, initiate lifestyle changes and
treatment strategies for metabolic syndrome. (See
Section 7.12.3 of STEMI 2004 Guideline.)
3. If waist circumference (measured horizontally at the iliac crest) is 35
inches (89 cm) or greater in women and 40 inches (102 cm) or greater in
men, it is useful to initiate lifestyle changes and consider treatment
strategies for metabolic syndrome as indicated.
I (B) Modified recommendation
(changed text)
Diabetes Management
Goal: HbA1c less than 7%
Appropriate hypoglycemic therapy to achieve near-
normal fasting plasma glucose, as indicated by
HbA1c.
1. It is recommended to initiate lifestyle and pharmacotherapy to achieve
near-normal HbA1c.
I (B) Modified recommendation
(changed text)
Treatment of other risk factors (e.g., physical
activity, weight management, blood pressure, and
cholesterol management). (See Section 7.12.9 in
the 2004 STEMI Guideline.)
2. Beginning vigorous modification of other risk factors (e.g., physical activity,
weight management, blood pressure control, and cholesterol management
as recommended above) is beneficial.
I (B) Modified recommendation
(changed text)
3. Coordination of diabetic care with the patient’s primary care physician or
endocrinologist is beneficial.
I (C) New recommendation
Antiplatelet Agents/Anticoagulants: Aspirin
Start and continue indefinitely aspirin 75 to 162
mg/d if not contraindicated.
1. For all post-PCI STEMI stented patients without aspirin resistance,
allergy, or increased risk of bleeding, aspirin 162 mg to 325 mg daily
should be given for at least 1 month after BMS implantation, 3
months after sirolimus-eluting stent implantation, and 6 months after
paclitaxel-eluting stent implantation, after which long-term aspirin
use should be continued indefinitely at a dose of 75 mg to 162 mg
daily.
I (B) Modified recommendation
(changed text)
2. In patients for whom the physician is concerned about risk of
bleeding lower-dose 75 mg to 162 mg of aspirin is reasonable during
the initial period after stent implantation.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Clopidogrel
Consider clopidogrel 75 mg/d or warfarin if aspirin
is contraindicated.
1. For all post-PCI patients who receive a DES, clopidogrel 75 mg daily
should be given for at least 12 months if patients are not at high risk
of bleeding. For post-PCI patients receiving a BMS, clopidogrel should
be given for a minimum of 1 month and ideally up to 12 months
(unless the patient is at increased risk of bleeding; then it should be
given for a minimum of 2 weeks).
I (B) Modified recommendation
(changed text)
2. For all STEMI patients not undergoing stenting (medical therapy alone
or PTCA without stenting), treatment with clopidogrel should continue
for at least 14 days.
I (B) New recommendation
3. Long-term maintenance therapy (e.g., 1 year) with clopidogrel (75 mg
per day orally) is reasonable in STEMI patients regardless of whether
they undergo reperfusion with fibrinolytic therapy or do not receive
reperfusion therapy.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Warfarin
Manage warfarin to INR 2.5 to 3.5 in post-STEMI patients
when clinically indicated or for those not able to take
aspirin or clopidogrel. (See Sections 7.12.5 and 7.12.11
and Figure 37 in the 2004 STEMI Guideline for further
details of antiplatelet and anticoagulant therapy at hospital
discharge.)
1. Managing warfarin to an INR equal to 2.0 to 3.0 for paroxysmal or chronic
atrial fibrillation or flutter is recommended, and in post-MI patients when
clinically indicated (e.g., atrial fibrillation, left ventricular thrombus).
I (A) Modified recommendation
(changed text)
2. Use of warfarin in conjunction with aspirin and/or clopidogrel is associated
with an increased risk of bleeding and should be monitored closely.
I (B) New recommendation
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3. In patients requiring warfarin, clopidogrel, and aspirin therapy, an INR
of 2.0 to 2.5 is recommended with low dose aspirin (75 mg to 81 mg)
and a 75 mg dose of clopidogrel.
I (C) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: ACE Inhibitors
ACE inhibitors in all patients indefinitely; start early
in stable high-risk patients (anterior MI, previous
MI, Killip class greater than or equal to II [S3
gallop, rales, radiographic CHF], LVEF less than
0.40).
1. ACE inhibitors should be started and continued indefinitely in all patients
recovering from STEMI with LVEF less than or equal to 40% and for those
with hypertension, diabetes, or chronic kidney disease, unless
contraindicated.
I (A) Modified recommendation
(changed text)
2. ACE inhibitors should be started and continued indefinitely in patients
recovering from STEMI who are not lower risk (lower risk defined as those
with normal LVEF in whom cardiovascular risk factors are well controlled
and revascularization has been performed), unless contraindicated.
I (B) New recommendation
3. Among lower risk patients recovering from STEMI (i.e., those with normal
LVEF in whom cardiovascular risk factors are well controlled and
revascularization has been performed) use of ACE inhibitors is reasonable.
IIa (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Angiotensin Receptor Blockers
Angiotensin receptor blockers in patients who are
intolerant of ACE inhibitors and with either clinical
or radiological signs of heart failure or LVEF less
than 0.40.
1. Use of angiotensin receptor blockers is recommended in patients who are
intolerant of ACE inhibitors and have HF or have had an MI with LVEF less
than or equal to 40%.
I (A) Modified recommendation
(changed text)
2. It is beneficial to use angiotensin receptor blocker therapy in other
patients who are ACE-inhibitor intolerant and have hypertension.
I (B) New recommendation
3. Considering use in combination with ACE inhibitors in systolic dysfunction
HF may be reasonable.
IIb (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade
Aldosterone blockade in patients without significant
renal dysfunction or hyperkalemia¶¶ who are
already receiving therapeutic doses of an ACE
inhibitor, have an LVEF less than or equal to 0.40, and
have either diabetes or heart failure. (See Section
7.12.6 in the 2004 STEMI Guideline.)
1. Use of aldosterone blockade in post-MI patients without significant renal
dysfunction or hyperkalemia¶¶ is recommended in patients who are
already receiving therapeutic doses of an ACE inhibitor and beta blocker,
have an LVEF of less than or equal to 40%, and have either diabetes or
HF.
I (A) Modified recommendation
(changed text)
Beta Blockers
Start in all patients. Continue indefinitely. Observe
usual contraindications. (See Section 7.12.7 in the
2004 STEMI Guideline.)
1. It is beneficial to start and continue beta-blocker therapy indefinitely in all
patients who have had MI, acute coronary syndrome, or LV dysfunction
with or without HF symptoms, unless contraindicated.
I (A) Modified recommendation
(changed text)
Influenza Vaccination
1. Patients with cardiovascular disease should have an annual influenza
vaccination.
I (B) New recommendation
Recommendations in bold type are those the writing committee felt deserved extra emphasis. The 2007 STEMI recommendations are written in complete sentences,
in accordance with ACC/AHA Guidelines methodology. “No content change” indicates the updated recommendation now includes an LOE and COR and a verb
consistent with that LOE and COR as outlined in the ACC/AHA LOE/COR table (Table 1).
*For compelling indications for individual drug classes in specific vascular diseases, see the Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)87a).
†Non–HDL-C indicates total cholesterol minus HDL-C.
‡Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury.
§When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C less than 70 mg per dL is the chosen target, consider
drug titration to achieve this level to minimize side effects and cost. When LDL-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels,
it generally is possible to achieve reductions of greater than 50% in LDL-C levels by either statins or LDL-C–lowering drug combinations.
Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin.
¶Treat to a goal of non–HDL-C substantially less than 130 mg per dL.
**Dietary supplement niacin must not be used as a substitute for prescription niacin.
††The use of resin is relatively contraindicated when triglycerides are greater than 200 mg per dL.
‡‡The combination of high-dose statin plus fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination.
§§Patients with very high triglycerides should not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are greater
than 200 mg per dL.
Creatinine should be less than 2.5 mg per dL in men and less than 2.0 mg per dL in women.
¶¶Potassium should be less than 5.0 mEq/L.
ACE indicates angiotensin-converting enzyme; BMI, body mass index; CHF, congestive heart failure; COR, classification of recommendation; HDL-C, high-density
lipoprotein cholesterol; HF, heart failure; INR, international normalized ratio; LDL-C, low-density lipoprotein cholesterol; LOE, level of evidence; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.
drugs;
320 Circulation January 15, 2008
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 13. Antiplatelet Therapy
The selective COX-2 inhibitors and other nonselective
NSAIDs have been associated with increased cardiovascular
risk. The risk appears to be amplified in patients with
established cardiovascular disease.15,18,19
Gislason et al. analyzed the risk of rehospitalization for MI
and death related to the use of NSAIDs, including selective
COX-2 inhibitors, in patients with prior MI.17 All patients with
first-time MI between 1995 and 2002 and all prescription claims
for NSAIDs after discharge were identified from nationwide
Danish administrative registers. The risk of death and rehospi-
talization for MI associated with the use of selective COX-2
inhibitors and nonselective NSAIDs was studied with the use of
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 narcotic analg
• COX-
N
• Nonacetyla
• Non COX-2 s
• NSAID
COX-
Select patients
at low risk of
thrombotic events
Prescribe lowest dose
required to control symptoms
Add ASA 81 mg and PPI to
patients at increased risk of
thrombotic events *
* Addition of ASA may not be suffic ient
protection against thrombotic events
Figure 4. Stepped-Care Approach to Management of Musculosk
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 An AHA scientific statement on the use of NSAIDs con-
cluded that the risk of cardiovascular events is proportional to
COX-2 selectivity and the underlying risk in the patient.20
Nonpharmacological approaches were recommended as the first
line of treatment, followed by the stepped-care approach to
pharmacological therapy shown in Figure 4 (Table 15). Al-
though not preferred, analgesic doses of aspirin may be a
reasonable option for some patients. This approach provides an
antiplatelet effect but confers a higher risk of bleeding than
low-dose aspirin plus another analgesic.89
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In the article by Antman et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the
Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines” that
appeared in the January 15, 2008, issue of the journal, folio information for Circulation and the
issue date of the version that appeared in the Journal of the American College of Cardiology were
incomplete. The complete citation is Circulation. 2008;117:296–329. This article was copub-
lished in the January 15, 2008, issue of the Journal of the American College of Cardiology. The
current online version of the article has been corrected.
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